Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,444.05
+1.2%
$1,242.25
$850.51
▼
$1,460.00
$1.34T0.43.00 million shs2.08 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.75%+5.24%+19.24%+22.14%+41.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,444.05
+1.2%
$1,242.25
$850.51
▼
$1,460.00
$1.34T0.43.00 million shs2.08 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.75%+5.24%+19.24%+22.14%+41.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,416.64-1.90% Downside

Current Analyst Ratings Breakdown

Latest LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy ➝ Hold
11/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,610.00 ➝ $1,700.00
11/2/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,440.00 ➝ $1,600.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B+) ➝ Buy (B)
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,300.00 ➝ $1,550.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,425.00 ➝ $1,625.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,650.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,497.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,330.00 ➝ $1,500.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,376.00 ➝ $1,612.00
(Data available from 11/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B20.84$25.43 per share56.78$42.81 per share33.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8146.8728.481.7131.90%86.76%22.03%N/A

Latest LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.48%+15.18%22.46%11 Years

Latest LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.48%11/13/202611/13/202612/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.74 million939.43 millionOptionable

Recent News About These Companies

What Is The Market Seeing In Eli Lilly Stock?
What Eli Lilly Doubters Overlooked
Pharmaceutical Stocks Worth Watching - November 13th
Best Healthcare Stocks To Follow Today - November 13th
HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs
Eli Lilly, obesity drug manufacturer, comes to Pennsylvania
ETFs Are Buying Eli Lilly (LLY) on Nov. 11
Eli Lilly Stocks Rise as China Approves Orforglipron Weight-Loss Pill
Mapping the Market: Eli Lilly shares ready to rally again

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,444.05 +16.77 (+1.17%)
Closing price 11/13/2026 03:59 PM Eastern
Extended Trading
$1,438.50 -5.55 (-0.38%)
As of 11/13/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.